Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial | Synapse

August 10, 2010Open Access

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Perez et al. (Tue,) studied this question.

synapsesocial.com/papers/69da4fde84371aa676a3d12e https://doi.org/https://doi.org/10.1200/jco.2009.26.2154

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo